Surgical Site Infection (SSI) Epidemiology Forecast 2025-2034

Surgical site infection (SSI) is a significant cause of morbidity and mortality following a surgical procedure although the majority of these infections are considered preventable. It is estimated that 2% to 4% of all patients who undergo an inpatient surgical procedure are affected by surgical site infections.

Surgical Site Infection (SSI) Epidemiology Forecast Report Coverage

The “Surgical Site Infection (SSI) Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of surgical site infection (SSI). It projects the future incidence and prevalence rates of surgical site infection (SSI) across various populations. The study covers age, gender, and type as major determinants of the surgical site infection (SSI)-affected population. The report highlights patterns in the prevalence of surgical site infection (SSI) over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of surgical site infection (SSI) in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Surgical Site Infection (SSI) Disease Overview

Surgical site infections (SSIs) pose a major cause of postoperative complications, increasing patient morbidity, mortality, and healthcare costs. They can occur due to contamination during surgery, poor or improper infection control practices in the healthcare facility, and patient-related factors (diabetes, obesity, or immune deficiencies), among others. SSIs can be superficial, in which only the skin is infected. On the other hand, in severe cases, the infection can affect deeper tissues, organs, or even implanted materials.

Surgical Site Infection (SSI): Treatment Overview

Treatment of surgical site infections depends on the type, severity, and causative pathogen. Effective management of this complication usually involves a combination of antimicrobial therapy, wound care, and in certain cases, a surgical procedure. Superficial infections may require 5 to 7 days of antimicrobial therapy whereas deep or organ infections may need several weeks. Moreover, the rise of multidrug-resistant organisms is augmenting the demand for advanced antibiotics such as vancomycin, linezolid, or daptomycin.

Epidemiology

The surgical site infection (SSI) epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for surgical site infection (SSI) by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for surgical site infection (SSI) and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• According to a systematic review and meta-analysis (2023), the global pooled incidence of surgical site infection (SSI) was estimated to be 2.5%, with the highest incidence reported in the African region.
• Between 2018 and 2020, around 20,000 surgical site infections were reported from over 1.2 million surgeries in 13 EU/EEA countries that took part in SSI surveillance coordinated by the European Centre for Disease Prevention and Control (ECDC).
• Approximately 11% of patients in low- and middle-income countries are affected by surgical site infections after a surgical procedure, according to the World Health Organisation (WHO).
• Surgical site infections are reported to be the most expensive type of healthcare-associated infection, costing an estimated USD 3.3 billion annually. They increase hospital stays by about 9.7 days and add over USD 20,000 to the cost of each hospital admission.

Country-wise Surgical Site Infection (SSI) Epidemiology

The surgical site infection (SSI) epidemiology data and findings for the United States, EU-4 (Germany, Spain, Italy, France), the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of surgical site infection (SSI) varies between countries owing to differences in healthcare infrastructure, surgical techniques, and infection control measures, among others. As per the World Health Organisation (WHO), surgical site infections are responsible for 400,000 extra hospital days for affected patients at an additional financial expense of USD 900 million annually in the United States.

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of surgical site infection (SSI) based on several factors.
• Surgical Site Infection (SSI) Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The report helps to identify the patient population and the unmet needs of surgical site infection (SSI) are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of surgical site infection (SSI) epidemiology in the 8 major markets?
• What will be the total number of patients with surgical site infection (SSI) across the 8 major markets during the forecast period?
• What was the country-wise prevalence of surgical site infection (SSI) in the 8 major markets in the historical period?
• Which country will have the highest number of surgical site infection (SSI) patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of surgical site infection (SSI) during the forecast period of 2025-2034?
• What are the currently available treatments for surgical site infection (SSI)?
• What are the disease risks, signs, symptoms, and unmet needs of surgical site infection (SSI)?

This product will be delivered within 3-5 business days.